

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康（南京）科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2617)**

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of TransThera Sciences (Nanjing), Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 26 August 2026 for the purposes of, amongst other matters, (i) considering and approving the unaudited consolidated interim results of the Company and its subsidiaries for the six months ended 30 June 2026 and its publication thereof; (ii) considering the declaration and payment of an interim dividend, if any; and (iii) transacting any other business.

By Order of the Board  
**TransThera Sciences (Nanjing), Inc.**  
**Dr. Frank Wu**  
*Chairman and Chief Executive Officer*

Hong Kong, 14 August 2026

*As at the date of this announcement, the Board comprises (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.*